Is Monosomy 13 a High-Risk Marker for Myeloma?
What Are Some Clinical Myeloma Relapse Predictors?
https://vimeo.com/796533863 Some multiple myeloma patients may relapse, but are there clinical predictors for relapse? Dr. Sikander Ailawadhi from the Mayo Clinic discusses mutations, clinical responses, and test results that may…
Why Do Some Myeloma Patients Experience Chronic Kidney Disease?
https://vimeo.com/796533707 What do multiple myeloma patients need to know about chronic kidney disease? Dr. Sikander Ailawadhi from the Mayo Clinic shares insight about incidence of kidney dysfunction, healthcare disparities, and…
Myeloma Patient Expert Q&A: Start Here
https://vimeo.com/796705764 In this myeloma patient expert Q&A, Mayo Clinic expert Dr. Sikander Ailawadhi provides highlights around the myeloma novel alphabet soup and actionable steps on how patients and care partners…
What AML Mutations Are Associated With Adverse Outcomes?
https://vimeo.com/794307363 Which acute myeloid leukemia (AML) mutations are linked to adverse outcomes? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares insight..Learn about different mutations, treatment…
BIPOC Patients Living With AML | Mortality Rate and Favorable Genetics
https://vimeo.com/794307299 How can acute myeloid leukemia (AML) disparities be addressed in BIPOC groups? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares insight. Learn about disparities,…
Challenges in Treating TP53-Mutated AML, Hope on the Horizon
https://vimeo.com/794307233 TP53-mutated acute myeloid leukemia (AML) treatment has some challenges. Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective. Learn about promising treatments on…
A Look at Ongoing Acute Myeloid Leukemia Phase III Trials
What are the acute myeloid leukemia (AML) Phase III clinical trials that are ongoing? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective about…
What Does Triplet Therapy in AML Mean for the Future?
https://vimeo.com/794307058 What do acute myeloid leukemia (AML) patients need to know about triplet therapy? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective. Learn…
A Look at Lower Intensity Chemotherapy in Untreated AML
Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses whether untreated acute myeloid leukemia (AML) can be treated with lower intensity chemotherapy. [ACT]IVATION TIP “Ask your physician…
AML Clinical Trials Critical to Treatment Breakthroughs and Improvements
https://vimeo.com/794306889 Why are acute myeloid leukemia (AML) clinical trials so critical? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective about clinical trials. Learn…
A Look at Treatment Strategies for High-Risk AML Patients
What acute myeloid leukemia (AML) treatments are available for high-risk patients? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses various mutations, potential for cure, and…